ipragliflozin trade names suglat pharmaceutical drug treatment type diabetes ipragliflozin jointly developed astellas pharma kotobuki pharmaceutical approved japan january russia may ipragliflozin sodiumglucose cotransporter inhibitor membrane proteins cell surface transfer glucose cells one subtype sglts plays key role reuptake glucose proximal tubule kidneys ipragliflozin reduces blood glucose levels inhibiting reuptake glucose selectively inhibiting efficacy safety ipragliflozin observed phase iii study monotherapy clinical studies used combination hypoglycemic agents types one placebocontrolled doubleblind study carried different sites korea taiwan patients type diabetes atlas weeks given period clear systems drugs besides metformin patients received either mg ipragliflozin placebo drugs identical physical forms patients prohibited using anti diabetic drugs metformin study ran weeks along followup period standard deviation hemoglobin ipragliflozin placebo groups respectively betweengroup difference p changes fasting plasma glucose bodyweight also significantly greater ipragliflozin group betweengroup differences mgdl kg respectively p common adverse events appeared upper respiratory infections urinary tract infections concluded ipragliflozin efficacious well however ipragliflozin currently observational case control clinical trial see longterm three years safety using ipragliflozin estimated completion trial october ipragliflozin also development type diabetes mellitus us europe countries three phase ii trials completed combination metformin since suglat top reimbursed drug japan peak sales reached million cost per patient reached per market selective inhibitors japan around billion yen suglats share market around sales suglat grew billion yen following availability longterm prescriptions may suglats share market selective inhibitors japan around projected sales jump way billion ipragliflozin first drug kind sold company japan therefore astellas focus marketing order maintain top share market astellas building postmarketing data regard efficacy safety ipragliflozin supplying information based data astellas aims increase market penetration ipragliflozin japanese market astellas additionally launched suglat republic korea feburic may boehringer ingelheim germany applied methods treatment pharmaceutical compositions uses thereof patent patent application included inhibitor april boehringer ingelheim applied usage inhibitors equine animals usage inhibitors animal study allows progression application humans national institute biological science beijing filed similar patent september january dalian university technology filed patent synthetic method additional patents synthesis intermediates leading types inhibitors httpsenwikipediaorgwikiipragliflozin